Dewpoint Therapeutics

Dewpoint Therapeutics

Biotechnologieforschung

Boston, MA 10.957 Follower:innen

Translating condensate biology into medicine.

Info

Dewpoint is the first company to apply the emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Merck, and Pfizer. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Branche
Biotechnologieforschung
Größe
51–200 Beschäftigte
Hauptsitz
Boston, MA
Art
Privatunternehmen
Gegründet
2018
Spezialgebiete
biomolecular condensates, oncology, neurodegeneration, cardiopulmonary, virology, insulin resistance und rare disease

Orte

Beschäftigte von Dewpoint Therapeutics

Updates

Ähnliche Seiten

Jobs durchsuchen

Finanzierung